{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:22:35Z","timestamp":1788092555828,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>The renin-angiotensin system (RAS) has proven to be involved in the pathophysiology of neurodegenerative diseases, such as Parkinson\u2019s disease (PD) and Alzheimer\u2019s disease (AD), serving as a potential therapeutic target and a disease burden marker. Studies have associated negative clinical outcomes with the activation of the classical RAS arm composed of the angiotensin-converting enzyme (ACE) and angiotensin (Ang) II, while suggested positive outcomes with the activation of the counter-regulatory RAS arm involving ACE2 and Ang-(1\u20137). Huntington\u2019s disease (HD) shares many pathological and clinical outcomes with AD and PD, but the evidence of direct involvement of RAS components in the pathophysiology of HD is still limited and needs further investigation. Herein, we investigated peripheral levels of the RAS components Ang II, Ang-(1\u20137), ACE, and ACE2 in controls, premanifest, and manifest HD gene carriers and their relationship with clinical outcomes. Peripheral blood samples were collected via phlebotomy, and plasma concentrations of RAS components were measured by Enzyme-Linked Immunosorbent Assay. Clinical evaluation included a questionnaire about socio-demographic characteristics, motor, and cognitive assessments. Results showed (1) no significant group differences in plasma concentrations of RAS components; (2) positive correlations between ACE2 and Verbal Fluency Test (VFT) scores; and (3) negative correlations between Ang II and Mini\u2013Mental State Examination scores. These results corroborate the proposed balance between the classical (ACE\/Ang II) and the counter-regulatory [ACE2\/Ang-(1\u20137)] arms of the RAS, with the former associated with negative clinical outcomes and the latter with positive effects in HD.<\/jats:p>","DOI":"10.3389\/fnins.2020.594945","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:10:29Z","timestamp":1608268229000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Peripheral Levels of Renin-Angiotensin System Components Are Associated With Cognitive Performance in Huntington\u2019s Disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Natalia P.","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela D.","family":"Colpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Furr Stimming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio L.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.410020406","article-title":"Huntington\u2019s chorea: selective depletion of activity of angiotensin coverting enzyme in the corpus striatum.","volume":"2","author":"Arregui","year":"1977","journal-title":"Ann. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0014-2999(78)90029-8","article-title":"Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington\u2019s disease and after intrastriatal kainic acid in rats.","volume":"52","author":"Arregui","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1471-4159.1986.tb04539.x","article-title":"Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington\u2019s disease caudate nucleus.","volume":"47","author":"Butterworth","year":"1986","journal-title":"J. Neurochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1152\/ajpregu.00476.2002","article-title":"Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression.","volume":"285","author":"Chabrashvili","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B5","year":"2011","journal-title":"Enroll-HD: A Prospective Registry Study in a Global Huntington\u2019s Disease Cohort."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1007\/s00018-004-4243-4","article-title":"Novel angiotensin peptides.","volume":"61","author":"Ferrario","year":"2004","journal-title":"Cell Mol. Life Sci."},{"key":"B7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0014-2999(95)00762-8","article-title":"Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders.","volume":"297","author":"Ge","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-2-1","article-title":"Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.","volume":"2","author":"Grammatopoulos","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"B10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/01.res.86.5.494","article-title":"NAD(P)H oxidase: role in cardiovascular biology and disease.","volume":"86","author":"Griendling","year":"2000","journal-title":"Circ. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"H736","DOI":"10.1152\/ajpheart.00937.2006","article-title":"Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7).","volume":"292","author":"Grobe","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/mds.20332","article-title":"Interrater agreement in the assessment of motor manifestations of Huntington\u2019s disease.","volume":"20","author":"Hogarth","year":"2005","journal-title":"Mov. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u2019s Disease Rating Scale: reliability and consistency.","volume":"11","year":"1996","journal-title":"Mov. Disord."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0217-7","article-title":"Angiotensin-converting enzyme 2 is reduced in Alzheimer\u2019s disease in association with increasing amyloid-beta and tau pathology.","volume":"8","author":"Kehoe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative Stress and Huntington\u2019s Disease: The Good. The Bad, and The Ugly.","volume":"5","author":"Kumar","year":"2016","journal-title":"J. Huntingtons Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euroneuro.2004.05.007","article-title":"Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.","volume":"15","author":"Kurosaki","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.","author":"Langbehn","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-9-49","article-title":"Increase of angiotensin II type 1 receptor auto-antibodies in Huntington\u2019s disease.","volume":"9","author":"Lee","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/jnr.23404","article-title":"Conversion of Abeta43 to Abeta40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme.","volume":"92","author":"Liu","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuropharm.2006.03.004","article-title":"Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.","volume":"51","author":"Munoz","year":"2006","journal-title":"Neuropharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems.","volume":"86","author":"Paul","year":"","journal-title":"Physiol. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems.","volume":"86","author":"Paul","year":"","journal-title":"Physiol. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2174\/15734021113099990003","article-title":"RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects.","volume":"9","author":"Pelisch","year":"2013","journal-title":"Curr. Hypertens Rev."},{"key":"B24","first-page":"1301","article-title":"The Anti-Inflammatory Potential of ACE2\/Angiotensin-(1-7)\/Mas Receptor Axis: Evidence from Basic and Clinical Research.","volume":"18","author":"Prestes","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"B25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","article-title":"The Prevalence of Huntington\u2019s Disease.","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.neurobiolaging.2006.02.018","article-title":"Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.","volume":"28","author":"Rey","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8653132","article-title":"Neuroimmunology of Huntington\u2019s Disease: Revisiting Evidence from Human Studies.","volume":"2016","author":"Rocha","year":"","journal-title":"Mediators Inflamm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jns.2016.07.031","article-title":"Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson\u2019s disease.","volume":"368","author":"Rocha","year":"","journal-title":"J. Neurol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3233\/JAD-180282","article-title":"Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-beta42 Burden in Alzheimer\u2019s Disease.","volume":"64","author":"Rocha","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","article-title":"The anti-inflammatory potential of ACE2\/angiotensin-(1-7)\/mas receptor axis: evidence from basic and clinical research.","volume":"18","author":"Rodrigues Prestes","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","article-title":"Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS.","volume":"31","author":"Rodriguez-Pallares","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment.","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics.","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas.","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/BF01717829","article-title":"Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseases.","volume":"65","author":"Schweisfurth","year":"1987","journal-title":"Klin. Wochenschr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.","volume":"169","author":"Simoes e Silva","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.27976","article-title":"Hypertension. Antihypertensive Use and the Delayed-Onset of Huntington\u2019s Disease.","volume":"35","author":"Steventon","year":"2020","journal-title":"Mov. Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jocn.2016.02.036","article-title":"The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer\u2019s disease: A meta-analysis.","volume":"33","author":"Zhuang","year":"2016","journal-title":"J. Clin. Neurosci."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2020.594945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:10:43Z","timestamp":1608268243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2020.594945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":38,"alternative-id":["10.3389\/fnins.2020.594945"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2020.594945","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"article-number":"594945"}}